Data suggests cannabis may dampen the strength or emotional impact of traumatic memories through synergistic mechanisms that might make it easier for people with PTSD to rest or sleep and to feel less anxious and less involved with flashback memories. Cannabidiol reduces anxiety in patients with generalized social anxiety disorder.
The authors present case histories indicating that a number of patients find cannabis (marihuana) useful in the treatment of their bipolar disorder. Some used it to treat mania, depression, or both. They stated that it was more effective than conventional drugs, or helped relieve the side effects of those drugs. One woman found that cannabis curbed her manic rages; she and her husband have worked to make it legally available as a medicine. Others described the use of cannabis as a supplement to lithium (allowing reduced consumption) or for relief of lithium’s side effects.
“Nearly half (45%) reported relief from insomnia. ”
“Daily users reported less depressed mood and more positive affect than non-users.”
ATTENTION DEFECIT HYPERACTIVITY DISORDER
By the end of the study, those who received cannabis treatment showed improvements in symptoms of hyperactivity, impulsivity and inattention. They also scored higher on measures of cognitive performance and emotional stability.
“Almost all respondents (97%) used medical cannabis primarily for relief of chronic pain.”
LOW BACK PAIN
Both preclinical and clinical data suggest that cannabinoids, derived from the Cannabis sativa plant, may be used to control symptoms such as spasticity and chronic pain. Inhaled cannabis significantly reduces objective measures of pain intensity compared to placebo in patients with MS.
” A substantial proportion of patients perceived cannabis as effective for relief of abdominal pain”
“The frequency of migraine headache was decreased with medical marijuana use.”
There is evidence that the cannabinoid receptors CB1 and CB2 may be involved in the control of spasticity in multiple sclerosis. Further evidence and data confirms the efficacy of cannabinoids in reducing spasticity in patients with MS, suggesting a higher sensitivity and specificity of the stretch reflex compared with other measures. As an objective and quantitative measure of spasticity, the stretch reflex is particularly useful to assess the effects of cannabinoids on spinal excitability. Further evidence and data suggests cannabis is reported to decrease spasticity in patients with multiple sclerosis and was significant improvement in patient ratings of spasticity compared to placebo. These positive findings in a treatment failure population suggest a role for THC in the treatment of spasticity in multiple sclerosis says a marijuana doctor associated with the NHSOF MD group.
“RESEARCH HAS CONFIRMED THAT UNDERLYING ENDOCANNABINOID DEFICIENCIES INDEED PLAY A ROLE IN …FIBROMYALGIA…AND A GROWING LIST OF OTHER MEDICAL CONDITIONS”
DIABETIC PAIN NEUROPATHY
“Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain.”
“Cannabinoids produce their effects via several cannabinoid receptors and it is important to identify the key cannabinoids and their receptors that are involved in chondroprotection”
This review summarizes the promising results that have been recently obtained in support of the therapeutic value of cannabinoids for osteoarthritis management.
“addition of Aja (a synthetic cannabinoid) reduced the secretion of il-6 from activated cells, suggesting that Aja may have a value for treatment of joint inflammation in patients with systemic lupus erythematosus”
The cannabinoids found in cannabis have therapeutic potential against osteoporosis because of their interaction with the CB1 and CB2 cannabinoid receptor
Study results indicate that cannabis may have a positive effect on disease activity, as reflected by a reduction in disease activity index and in the need for other drugs and surgery. Preclinical studies demonstrate that activation of the CB1 and CB2 cannabinoid receptors exert biological functions on the gastrointestinal tract. A randomized placebo-controlled trial, inhaled cannabis was reported to decrease Crohn’s disease symptoms in subjects with a treatment-resistant form of the disease. Nearly half of the patients in the trial achieved disease remission as reported by a group of Orlando medical marijuana Doctors.
Beneficial effect of the non-psychotropic plant cannabinoid on experimental inflammatory bowel disease.
marijuana has been found to be the most effective and rapid mechanism for relaying the active compounds to the brain, thereby allowing the sufferer to feel immediate relief from pain as well as offering better control over medication levels.
” addition of Aja (a synthetic cannabinoid) reduced the secretion of il-6 from activated cells, suggesting that Aja may have a value for treatment of joint inflammation in patients with systemic lupus erythematosus”
“CANNABINOIDS…. CAN PLAY A PROTECTIVE ROLE IN AUTOIMMUNE CONDITIONS”
Autism is a debilitating condition with symptoms that include anxiety, panic attacks, disruptive and violent behaviors, insomnia, and irritability (comparable to what is seen in PTSD), and a decreased ability to communicate (comparable to what is seen in Parkinson’s Disease and ALS)
“in one case study, a boy with autism was treated with daily dronabinol [synthetic THC] for six months and was noted to have improvement in hyperactivity, irritability, lethargy, stereotyped behaviors and speech”
Dystonia and Parkinson’s Disease are comparable in that they are both debilitating movement disorders.